Award
National Eye Institute 1R21EY037470-01
Mutation-independent therapy for retinal degenerations caused by PRPH2 mutations
Recipient
University of Houston
Award Amount
$431,750.00
Ceiling
$431,750.00
Awarded
July 21, 2025
Identifier
1R21EY037470-01
The award supports research to develop a mutation-independent therapy for retinal degenerations caused by PRPH2 mutations by reducing rhodopsin levels using antisense oligonucleotide treatment in mouse models.
Description
This project aims to develop a universal therapy for retinal degenerations caused by PRPH2 mutations by reducing rhodopsin levels, potentially improving patient outcomes. The study involves using rhodopsin-specific antisense oligonucleotide (mRho-ASO) treatment in mouse models expressing different mutant forms of PRPH2, assessing efficacy through various functional and structural measures.